Skip to main content
Premium Trial:

Request an Annual Quote

Dx Focus: Roche's CMV Viral Load Test; Meridian's Illumigene Group A Strep Assay


Roche this week announced the commercial availability of a molecular test for cytomegalovirus viral load.

Physicians can use information from the test to help them manage patients diagnosed with the disease, especially patients whose immune systems have been suppressed for solid organ transplantation, Roche said.

The new test is based on real-time PCR and runs on Roche's fully automated Cobas AmpliPrep/Cobas TaqMan system for viral load monitoring of multiple infectious diseases. The system can be combined with the Cobas p 630 instrument, which provides integrated pre-analytical primary tube handling.

Roche said its new CMV viral load test standardizes CMV viral load monitoring with traceability to the World Health Organization international CMV standard.

The test received pre-market approval from the US Food and Drug Administration in July.

Meridian Bioscience has received clearance from the US Food and Drug Administration for its Illumigene assay for group A streptococcus.

The new test uses loop-mediated isothermal amplification technology to detect Streptococcus pyogenes in throat samples. The test procedure is simple and highly sensitive, requires no capital equipment, and can be performed in less than an hour, Meridian said. All reagents and disposables are contained in the test kit and can be stored at room temperature.

Acute pharyngitis is one of the most frequent illnesses for which pediatricians and other primary care physicians are consulted, with an estimated 15 million visits per year in the United States, Meridian said. Approximately 20 to 30 percent of children seeking physician care are diagnosed with Group A Strep pharyngitis, typically by rapid antigen testing or throat swab culture. Studies have shown that culture may miss up to 10 percent of true positives.

The Scan

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.

Breast Cancer Risk Gene Candidates Found by Multi-Ancestry Low-Frequency Variant Analysis

Researchers narrowed in on new and known risk gene candidates with variant profiles for almost 83,500 individuals with breast cancer and 59,199 unaffected controls in Genome Medicine.

Health-Related Quality of Life Gets Boost After Microbiome-Based Treatment for Recurrent C. Diff

A secondary analysis of Phase 3 clinical trial data in JAMA Network Open suggests an investigational oral microbiome-based drug may lead to enhanced quality of life measures.

Study Follows Consequences of Early Confirmatory Trials for Accelerated Approval Indications

Time to traditional approval or withdrawal was shorter when confirmatory trials started prior to accelerated approval, though overall regulatory outcomes remained similar, a JAMA study finds.